CoChat

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis

Open access
Brown, Kevin K., Flaherty, Kevin R., Cottin, Vincent, Raghu, Ganesh, Inoue, Yoshikazu, Azuma, Arata, Huggins, John T., Richeldi, Luca, Stowasser, Susanne, Stansen, Wibke, Schlenker-Herceg, Rozsa, Maher, Toby M., Wells, Athol U. · 2019 · Respiratory Medicine
Cited by 44

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND In the INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing of disease progression. We characterised the effects of nintedanib on physiologic outcomes using pooled data from the INPULSIS® trials. METHODS Post-hoc analyses included changes in FVC over time, cumulative distribution of patients by change in FVC % predicted, and annual rate of decline in FVC in subgroups by diffusing capacity of the lung for carbon monoxide (DLco) and composite physiologic index (CPI) at baseline. Changes from baseline in DLco and oxygen saturation by pulse oximetry (SpO2) were pre-specified. RESULTS Nintedanib significantly reduced FVC decline versus placebo from week 12. A higher proportion of patients treated with nintedanib than placebo had an improvement or no decline in FVC % predicted, whereas a smaller proportion had absolute declines in FVC ≥5% or ≥10% predicted from baseline to week 52. The effect of nintedanib on FVC decline was similar in patients with baseline DLco >40% versus ≤40% predicted or CPI ≤45 versus >45. There were no significant differences between nintedanib and placebo in change from baseline in DLco % predicted, CPI, or SpO2 at week 52. However, change (deterioration) in CPI was significantly lower with nintedanib versus placebo in patients with CPI > 45 at baseline (1.0 versus 2.9) and CPI >55 at baseline (-1.2 versus 3.3). CONCLUSIONS A range of physiologic outcome measures in the INPULSIS® trials support the effect of nintedanib on reducing disease progression in patients with IPF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.rmed.2018.11.012

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 44

Metadata

Authors
Brown, K. K., Flaherty, K. R., Cottin, V., Raghu, G., Inoue, Y., Azuma, A., Huggins, J. T., Richeldi, L., Stowasser, S., Stansen, W., Schlenker-Herceg, R., Maher, T. M., & Wells, A. U.
Venue
Respiratory Medicine
Publisher
Elsevier BV
Published
2019-01
Volume
146
Pages
42-48
ISSN
0954-6111 (ISSN-L)
OpenAlex
W2901235303
Cited by
44
References
12
FWCI
3.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1016/j.rmed.2018.11.012
The paper
Brown, K. K., Flaherty, K. R., Cottin, V., Raghu, G., Inoue, Y., Azuma, A., Huggins, J. T., Richeldi, L., Stowasser, S., Stansen, W., Schlenker-Herceg, R., Maher, T. M., & Wells, A. U. (2019). Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine. https://doi.org/10.1016/j.rmed.2018.11.012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.